Collegium Pharmaceutical Inc (COLL)vsTeva Pharma Industries Ltd ADR (TEVA)
COLL
Collegium Pharmaceutical Inc
$33.45
+2.11%
HEALTHCARE · Cap: $1.12B
TEVA
Teva Pharma Industries Ltd ADR
$32.20
+3.14%
HEALTHCARE · Cap: $40.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 2079% more annual revenue ($17.35B vs $796.33M). COLL leads profitability with a 9.4% profit margin vs 9.0%. COLL trades at a lower P/E of 16.8x. TEVA earns a higher WallStSmart Score of 66/100 (B-).
COLL
Buy50
out of 100
Grade: C-
TEVA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.3%
Fair Value
$385.32
Current Price
$33.45
$351.87 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Smaller company, higher risk/reward
Earnings declined 46.6%
Distress zone — elevated risk
Elevated debt levels
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on Return on Equity, P/E Ratio.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.
Bear Case : COLL
The primary concerns for COLL are Market Cap, EPS Growth, Altman Z-Score. Debt-to-equity of 2.59 is elevated, increasing financial risk.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
TEVA carries more volatility with a beta of 0.85 — expect wider price swings.
COLL is growing revenue faster at 8.9% — sustainability is the question.
COLL generates stronger free cash flow (57M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (66/100 vs 50/100). COLL offers better value entry with a 88.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?